Study of the mTOR Inhibitor Temsirolimus(CCI-779) in Patients With CA125 Only Relapse of Ovarian Cancer. A Phase II Study by the Hellenic Cooperative Oncology Group.
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2011
At a glance
- Drugs Temsirolimus (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 09 Nov 2011 Planned End Date changed from 1 Dec 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 09 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.